Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00940602 · ClinicalTrials.gov registry record · Phase 2
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
NCT00940602 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 225 participants.
The verdict
NCT00940602, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
Study Summary
This was a randomized, double-blind trial to evaluate deferasirox vs placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload .The trial was conducted in 17 countries, started in 2010 and ended in 2018.
Interventions
- DRUG Placebo
- DRUG Deferasirox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2010-03-22 |
| Est. Completion | 2018-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00940602
The ClinicalTrials.gov registry entry for NCT00940602 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00940602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00940602 about?
NCT00940602 is a clinical study titled "Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study". This was a randomized, double-blind trial to evaluate deferasirox vs placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload .The trial was conducted in 17 countries, started in 2010 and ended in 2018.
What is the current status of trial NCT00940602?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2010-03-22. Estimated completion is 2018-02-27.
What interventions are being tested in trial NCT00940602?
The interventions under investigation include: Placebo (DRUG), Deferasirox (DRUG).
Who is sponsoring clinical trial NCT00940602?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.